New and different approaches needed for the design and execution of Alzheimer's clinical trials

By Maria C. Carrillo, Bruno Vellas Results of recent Alzheimer’s disease (AD) clinical trials have been mixed. Both the bapineuzumab and solanezumab trials did not reach planned end points, although prespecified subgroup and pooled analyses of results in participants with mild AD given solanezumab demonstrated signs of efficacy. Despite these results, there is much to learn Read & Research Alzheimer’s More

Leave a Reply